274 related articles for article (PubMed ID: 23632480)
21. Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype.
Singh A; Wu H; Zhang P; Happel C; Ma J; Biswal S
Mol Cancer Ther; 2010 Aug; 9(8):2365-76. PubMed ID: 20682644
[TBL] [Abstract][Full Text] [Related]
22. Expression and promoter methylation analysis of ATP-binding cassette genes in pancreatic cancer.
Chen M; Xue X; Wang F; An Y; Tang D; Xu Y; Wang H; Yuan Z; Gao W; Wei J; Zhang J; Miao Y
Oncol Rep; 2012 Jan; 27(1):265-9. PubMed ID: 21956451
[TBL] [Abstract][Full Text] [Related]
23. Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
Sun YL; Kathawala RJ; Singh S; Zheng K; Talele TT; Jiang WQ; Chen ZS
Anticancer Drugs; 2012 Sep; 23(8):865-73. PubMed ID: 22614107
[TBL] [Abstract][Full Text] [Related]
24. Role of the breast cancer resistance protein (ABCG2) in drug transport.
Mao Q; Unadkat JD
AAPS J; 2005 May; 7(1):E118-33. PubMed ID: 16146333
[TBL] [Abstract][Full Text] [Related]
25. Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.
Natarajan K; Xie Y; Baer MR; Ross DD
Biochem Pharmacol; 2012 Apr; 83(8):1084-103. PubMed ID: 22248732
[TBL] [Abstract][Full Text] [Related]
26. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G
J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522
[TBL] [Abstract][Full Text] [Related]
27. Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells.
To KK; Polgar O; Huff LM; Morisaki K; Bates SE
Mol Cancer Res; 2008 Jan; 6(1):151-64. PubMed ID: 18234970
[TBL] [Abstract][Full Text] [Related]
28. Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors.
Lemos C; Jansen G; Peters GJ
Br J Cancer; 2008 Mar; 98(5):857-62. PubMed ID: 18253130
[TBL] [Abstract][Full Text] [Related]
29. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
[TBL] [Abstract][Full Text] [Related]
30. Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export.
Katayama R; Koike S; Sato S; Sugimoto Y; Tsuruo T; Fujita N
Cancer Sci; 2009 Nov; 100(11):2060-8. PubMed ID: 19673889
[TBL] [Abstract][Full Text] [Related]
31. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation.
Haimeur A; Conseil G; Deeley RG; Cole SP
Curr Drug Metab; 2004 Feb; 5(1):21-53. PubMed ID: 14965249
[TBL] [Abstract][Full Text] [Related]
32. Enhancing chemosensitivity in ABCB1- and ABCG2-overexpressing cells and cancer stem-like cells by an Aurora kinase inhibitor CCT129202.
Cheng C; Liu ZG; Zhang H; Xie JD; Chen XG; Zhao XQ; Wang F; Liang YJ; Chen LK; Singh S; Chen JJ; Talele TT; Chen ZS; Zhong FT; Fu LW
Mol Pharm; 2012 Jul; 9(7):1971-82. PubMed ID: 22632055
[TBL] [Abstract][Full Text] [Related]
33. Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).
Ni Z; Bikadi Z; Rosenberg MF; Mao Q
Curr Drug Metab; 2010 Sep; 11(7):603-17. PubMed ID: 20812902
[TBL] [Abstract][Full Text] [Related]
34. miR-145 inhibits migration and invasion of glioma stem cells by targeting ABCG2.
Shi L; Wang Z; Sun G; Wan Y; Guo J; Fu X
Neuromolecular Med; 2014 Jun; 16(2):517-28. PubMed ID: 24777293
[TBL] [Abstract][Full Text] [Related]
35. Correlation between adenosine triphosphate (ATP)-binding cassette transporter G2 (ABCG2) and drug resistance of esophageal cancer and reversal of drug resistance by artesunate.
Wang L; Liu L; Chen Y; Du Y; Wang J; Liu J
Pathol Res Pract; 2018 Sep; 214(9):1467-1473. PubMed ID: 30104076
[TBL] [Abstract][Full Text] [Related]
36. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
[TBL] [Abstract][Full Text] [Related]
37. LRIG1, human EGFR inhibitor, reverses multidrug resistance through modulation of ABCB1 and ABCG2.
Liu B; Guo Z; Dong H; Daofeng T; Cai Q; Ji B; Zhang S; Wu L; Wang J; Wang L; Zhu X; Liu Y; Chen Q
Brain Res; 2015 Jun; 1611():93-100. PubMed ID: 25801120
[TBL] [Abstract][Full Text] [Related]
38. Tie2-mediated multidrug resistance in malignant gliomas is associated with upregulation of ABC transporters.
Martin V; Xu J; Pabbisetty SK; Alonso MM; Liu D; Lee OH; Gumin J; Bhat KP; Colman H; Lang FF; Fueyo J; Gomez-Manzano C
Oncogene; 2009 Jun; 28(24):2358-63. PubMed ID: 19421150
[TBL] [Abstract][Full Text] [Related]
39. Cellular folate status modulates the expression of BCRP and MRP multidrug transporters in cancer cell lines from different origins.
Lemos C; Kathmann I; Giovannetti E; Beliën JA; Scheffer GL; Calhau C; Jansen G; Peters GJ
Mol Cancer Ther; 2009 Mar; 8(3):655-64. PubMed ID: 19240161
[TBL] [Abstract][Full Text] [Related]
40. Valproic Acid-Induced Upregulation of Multidrug Efflux Transporter ABCG2/BCRP via PPAR
Kukal S; Bora S; Kanojia N; Singh P; Paul PR; Rawat C; Sagar S; Bhatraju NK; Grewal GK; Singh A; Kukreti S; Satyamoorthy K; Kukreti R
Mol Pharmacol; 2023 Mar; 103(3):145-157. PubMed ID: 36414374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
